Kirby R S, Coppinger S W, Corcoran M O, Chapple C R, Flannigan M, Milroy E J
Department of Urology, Middlesex Hospital, London.
Br J Urol. 1987 Aug;60(2):136-42. doi: 10.1111/j.1464-410x.1987.tb04950.x.
Eighty patients with prostatic obstruction were entered into a double-blind parallel study of prazosin versus placebo. There were 25 withdrawals or exclusions, leaving 55 patients for analysis. Mean maximum flow rates increased significantly more in patients treated with prazosin than in those treated with placebo (P less than 0.005), but there was no significant reduction in maximum voiding pressure. The mean number of voids, recorded on diary cards, was reduced from an initial 10.0/24 h by 2.1 in the final week, a significantly greater reduction than in the placebo group (P less than 0.01). However, there were no statistically significant changes in the filling cystometrograms. When patients were classified as responders or non-responders in terms of bladder filling, urine flow, bladder emptying, weekly average of voids/24 h and nocturia, the proportion of patients responding to prazosin was significantly greater in all categories except bladder filling and emptying. It was concluded that prazosin at a dose of 2 mg bd is a safe and effective treatment for prostatic obstruction and may be used in patients awaiting surgery and those who are unfit for operation.
80例前列腺梗阻患者进入一项关于哌唑嗪与安慰剂的双盲平行研究。有25例退出或被排除，剩余55例患者进行分析。接受哌唑嗪治疗的患者平均最大尿流率的增加显著大于接受安慰剂治疗的患者（P<0.005），但最大排尿压力没有显著降低。记录在日记卡上的平均排尿次数在最后一周从最初的10.0次/24小时减少了2.1次，减少幅度显著大于安慰剂组（P<0.01）。然而，充盈性膀胱测压图没有统计学上的显著变化。当根据膀胱充盈、尿流、膀胱排空、每周平均排尿次数/24小时和夜尿症将患者分类为反应者或无反应者时，除膀胱充盈和排空外，所有类别中对哌唑嗪有反应的患者比例均显著更高。得出结论，每日两次服用2mg哌唑嗪是治疗前列腺梗阻的一种安全有效的方法，可用于等待手术的患者和不适合手术的患者。
